In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist, Viozan™ (AR-C68397AA) improves quality of life and perception of efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance Source: Annual Congress 2007 - New drugs for COPD Year: 2007
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009
Metabolism of ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
The antitussive effects of alpha7 (a7) nicotinic receptor agonists Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017
Positive interaction of carmoterol, a new long-acting β2 -agonist, with budesonide Source: Eur Respir J 2005; 26: Suppl. 49, 215s Year: 2005
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
CS-003, a novel triple neurokinin receptor antagonist, inhibits symptoms of respiratory diseases models in guinea pigs Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006